Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Saproterin in Amish PKU
NCT02677870Phase 4Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jan 2018
- Primary completion
- Nov 2018
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of sapropterin in phenylketonuria (PKU), sponsored by University Hospitals Cleveland Medical Center. Started Jan 2018; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT02677870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677870.